Mountain Pacific Partners

Mountain Pacific Partners is a venture capital firm based in Salt Lake City, Utah, that specializes in early-stage investments within the life sciences and biotech sectors. Established in 2017, the firm focuses on supporting innovation in these fields, particularly in the Mountain and Southwest regions of the United States, including Arizona, Nevada, and New Mexico, as well as in South Korea. Mountain Pacific Partners has launched multiple funds, including Fund NOW, which aims to enhance health security by reshoring critical healthcare product manufacturing, and Fund NEXT, which is dedicated to transforming healthcare delivery through innovative technologies and medical devices.

Akhil Agrawal

Managing Partner

Past deals in Utah

Alterra Medical

Seed Round in 2021
Alterra Medical LLC is a medical device company based in Salt Lake City, Utah, founded in 2019. The company specializes in the development, consulting, and strategic management of medical devices. Alterra Medical collaborates with innovators throughout the entire product lifecycle, from initial ideation and concept feasibility to validation and national distribution. Their clinically-trained sales team plays a crucial role in ensuring the successful commercialization of medical devices, facilitating partnerships that enhance the introduction of innovative solutions to the market.

Xenocor

Series A in 2020
Xenocor designs and develops single-use, fog-free, high-definition laparoscopic imaging equipment. Its products enable safe and superior imagery for minimally invasive surgical procedures, operating independently of a power grid.

1st Source Consulting

Seed Round in 2020
1st Source Consulting LLC is a business consulting firm based in Salt Lake City, Utah, established in 2019. The company specializes in a wide range of services, including accounting, funding, management, marketing, manufacturing, human resources, and legal support. By offering comprehensive business solutions, 1st Source Consulting aims to assist organizations in enhancing their operational efficiency and achieving their strategic goals.

Turner Imaging Systems

Series B in 2019
Turner Imaging Systems, Inc. is a company based in Orem, Utah, that specializes in the development, manufacturing, and marketing of innovative x-ray imaging systems. Founded in 2016, the company has created the Smart-C Mini-C Arm, a battery-powered, portable fluoroscopy and x-ray imaging device designed for ease of use in various settings. This fully-functional mini-C-arm system allows users to acquire x-ray images conveniently and efficiently, enhancing the delivery of fluoroscopy services. Turner Imaging Systems aims to expand access to x-ray imaging, particularly in under-served areas and humanitarian efforts globally, thereby improving healthcare delivery in diverse environments.

Alterra Medical

Seed Round in 2019
Alterra Medical LLC is a medical device company based in Salt Lake City, Utah, founded in 2019. The company specializes in the development, consulting, and strategic management of medical devices. Alterra Medical collaborates with innovators throughout the entire product lifecycle, from initial ideation and concept feasibility to validation and national distribution. Their clinically-trained sales team plays a crucial role in ensuring the successful commercialization of medical devices, facilitating partnerships that enhance the introduction of innovative solutions to the market.

iVeena

Series B in 2019
Founded in 2006 by Bala Ambati, iVeena is a biopharmaceutical company based in Salt Lake City, Utah. It specializes in the development of novel drug candidates for ophthalmic diseases, with a focus on post-surgery cataract inflammation, macular degeneration, diabetic retinopathy, and glaucoma.

Navigen

Series A in 2018
Navigen Inc., established in 2014 and based in Salt Lake City, Utah, is a drug discovery and development company specializing in D-peptides. It focuses on advancing early-stage technologies from academia to clinical trials using non-dilutive funding. Navigen's product pipeline includes CPT31 for HIV treatment and prevention, a D-Peptide cancer immunotherapy targeting SIRPα, and a D-peptide anti-TNF therapy offering antigenicity advantages over current biologics. The company has raised approximately $40 million in non-dilutive funding to date, successfully advancing two programs to pre-IND studies with plans to file IND applications within 12-14 months.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.